Future cancer therapy with molecularly targeted therapeutics: Challenges and strategies

Biomolecules and Therapeutics

Volumn 19, Issue 4, 2011, Pages 371-389

  Kim, Mi Sook ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Combination of molecularly targeted cancer therapy; Personalized medicine; Small molecule kinase inhibitor; Targeted cancer therapy; Ubiquitin proteasome system (UPS) inhibitor; Ubiquitin like protein (UBL) conjugation system inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CARFILZOMIB; CEDIRANIB; CETUXIMAB; DASATINIB; DELANZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GW 0572016; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MLN 4924; MLN 9708; NILOTINIB; PAZOPANIB; PLACEBO; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACNE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; BREAST CANCER; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRY SKIN; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GENETIC HETEROGENEITY; GLIOBLASTOMA; HAIR COLOR; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALAISE; MANTLE CELL LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SARCOMA; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 81255195485     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2011.19.4.371     Document Type: Review

References (186)

1. Adam, S. J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S. and Elliott, P. J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
2. Adams, J. (2003) The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 29 (Suppl 1), 3-9.
3. Arrowsmith, J. (2011) Phase III and submission failures: 2007-2010. Nature Rev. Drug Discov. 10, 1.
4. Baker, S. J. and Reddy, E. P. (2010) Targeted inhibition of kinases in cancer therapy. Mt. Sinai J. Med. 77, 573-586.
5. Bareschino, M. A., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F. and Ciardiello, F. (2007) Erlotinib in cancer treatment. Annal. Oncol. 18 (Suppl 6), 35-41.
6. Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., Henthorn, L. and Richards, L. (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914.
7. Becker, K., Marchenko, N. D., Palacios, G. and Moll, U. M. (2008) A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle 7, 1205-1213.
8. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J. and Brownell, J. E. (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46.
9. Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C. 3rd., McIver, B., Burton, J. K., Webster, K. P., Bieber, C., Traynor, A. M., Flynn, P. J,. Goh, B. C., Tang, H., Ivy, S. P. and Erlichman, C. Endocrine Malignancies Disease Oriented Group. Mayo Clinic Cancer Center. Mayo Phase 2 Consortium. (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962-972.
10. Bjornsti, M. A. and Houghton, P. J. (2004) The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348.
11. Branford, S. and Hughes, T. (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol. Med. 125, 93-106.
12. Breccia, M. and Alimena, G. (2010) Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk. Res. 34, 129-134.
13. Brenner, H., Gondos, A. and Pulte, D. (2009) Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94, 270-275.
14. Brognard, J. and Hunter, T. (2011) Protein kinase signaling networks in cancer. Curr. Opin. Gene Dev. 21, 4-11.
15. Bukowski, R. M. (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 10, 635-645.
16. Cameron, D. A. and Stein, S. (2008) Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat. Clin. Pract. Oncol. 5, 512-520.
17. Cameron, D., Casey, M., Press M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., Chan, A., Campone, M., Viens, P., Davidson, N., Gorbounova, V., Raats, J. I., Skarlos, D., Newstat, B., Roychowdhury, D., Paoletti, P., Oliva, C., Rubin, S., Stein, S. and Geyer, C. E. A. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112, 5335-5343.
18. Carew, J. S., Giles, F. J. and Nawrocki, S. T. (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17.
19. Carter, C. A., Kelly, R. J. and Giaccone, G. (2009) Small-molecule inhibitors of the human epidermal receptor family. Expert Opin. Investig. Drugs 18, 1829-1842.
20. Casalini, P., Iorio, M. V., Galmozzi, E. and Menard, S. (2004) Role of HER receptors family in development and differentiation. J. Cell. Physiol. 200, 343-350.
21. Castaneda, C. A. and Gomez, H. L. (2009) Pazopanib: an antiangiogenic drug in perspective. Fut. Oncol. 5, 1335-1348.
22. Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., Ovaa, H., Berkers, C., Nicholson, B., Chao, T. H., Neuteboom, S. T., Richardson, P., Palladino, M. A. and Anderson, K. C. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419.
23. Chauhan, D., Hideshima, T. and Anderson, K. C. (2006) A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 95, 961-965.
24. Chauhan, D., Singh, A. V., Ciccarelli, B., Richardson, P. G., Palladino, M. A. and Anderson, K. C. (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115, 834-845.
25. Chiba, T. and Tanaka, K. (2004) Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr. Protein Pept. Sci. 5, 177-184.
26. Chiu, B. C. and Weisenburger, D. D. (2003) An update of the epidemiology of non-Hodgkin's lymphoma. Clin. Lymphoma 4, 161-168.
27. Chow, L. Q. and Eckhardt, S. G. (2007) Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25, 884-896.
28. Cohen, P. (2002) Protein kinases-the major drug targets of the twentyfirst centry? Nature Rev. Drug Discov. 1, 309-315.
29. Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D. Jr., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., Baird, A. and Pazdur, R. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10, 1212-1218.
30. Cohen, M. H., Johnson, J. R, Chattopadhyay, S., Tang, S., Justice, R., Sridhara, R. and Pazdur, R. (2010) Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 15, 1344-1351.
31. Colland, F. (2010) The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem. Soc. Trans. 38, 137-143.
32. Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V. N., Camonis, J., Calabrese, A., Borg-Capra, C., Sippl, W., Collura, V., Boissy, G., Rain, J. C., Guedat, P., Delansorne, R. and Daviet, L. (2009) Smallmolecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286-2295.
33. Corey, E. J. and Li, W. D. (1999) Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem. Pharm. Bull. (Tokyo), 47, 1-10.
34. Cortes-Funes, H., Gomez, C., Rosell, R., Valero, P., Garcia-Giron, C., Velasco, A., Izquierdo, A., Diz, P., Camps, C., Castellanos, D., Alberola, V., Cardenal, F., Gonzalez-Larriba, J. L., Vieitez, J. M., Maeztu, I,. Sanchez, J. J., Queralt, C., Mayo, C., Mendez, P., Moran, T. and Taron, M. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081-1086.
35. Dancey, J. E. and Chen, H. X. (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev. Drug Discov. 5, 649-659.
36. Daviet, L. and Colland, F. (2008) Targeting ubiquitin specific proteases for drug discovery. Biochimie 90, 270-283.
37. de Bettignies, G. and Coux, O. (2010) Proteasome inhibitors: dozens of molecules and still counting. Biochimie 92, 1530-1545.
38. Deininger, M. (2005) Resistance to imatinib: mechanisms and management. J. Natl. Compr. Cancer Netw. 3, 757-768.
39. Deininger, M. W., Goldman, J. M. and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
40. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., Desai, J., Fletcher, C. D., George, S., Bello, C. L, Huang, X., Baum, C. M. and Casali, P. G. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338.
41. Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., Shenk, K. D., Smyth, M. S., Sun, C. M., Vallone, M. K., Woo, T. M., Molineaux, C. J. and Bennett, M. K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383-6391.
42. Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F.,Shenk, K. D., Smyth, M. S., Sun, C. M., Vallone, M. K., Woo, T. M., Molineaux, C. J. and Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383-6391.
43. Dhillon, S. and Wagstaff, A. J. (2007) Lapatinib. Drugs 67, 2101-2108.
44. Dick, L. R. and Fleming, P. E. (2010) Building on bortezomib: secondgeneration proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15, 243-249.
45. Duffy, M. J., O'Donovan, N. and Crown, J. (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat. Rev. 37, 151-159.
46. Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., Klein, P., Miller, V. A., Ostland, M. A., Ramies, D. A., Sebisanovic, D., Stinson, J. A., Zhang, Y. R., Seshagiri, S. and Hillan, K. J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909.
47. Engelman, J. A. and Settleman, J. (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79.
48. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R. M. and TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134.
49. Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K. and Potts, B. C. (2009) Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 17, 2175-2180.
50. Force, T. and Kolaja, K. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Rev. Drug Discov. 10, 111-126.
51. Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R. and Scapozza, L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85.
52. Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K., Khan, K., Ahmed, S. S. L., Stebbing, J. and Knippschild, U. (2010) Kinases as targets in the treatment of solid tumors. Cell Signal 22, 984-1002.
53. Giamas, G., Stebbing, J., Vorgias, C. E. and Knippschild, U. (2007) Protein kinases as targets for cancer treatment. Pharmacogenomics 8, 1005-1016.
54. Giampaglia, M., Chiuri, V. E., Tinelli, A., De Laurentiis, M., Silvestris, N. and Lorusso, V. (2010) Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev. 36 (Suppl 3), S72-S79.
55. Goldberg, A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899.
56. Goldberg, A. L. (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 35, 12-17.
57. Golemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P. W., Mestan, J., Dugan, M., Alland, L., Griffin, J. D., Arlinghaus, R. B., Sun, T., Kantarjian, H. and Beran, M. (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11, 4941-4947.
58. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur F., Looijenga, L., Weber, B. L., Chiew, Y.-E., deFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M.-H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R., Futreal, P. A. and Stratton, M. R. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158.
59. Gupta, N., Liu, G., Berg, D., Kalebic, T. and Gomes-Navarro, J. (2010) Clinical pharmacokinetics of intravenous and oral MLN9708, an investigational proteasome inhibitor: an analysis of data from four Phase I monotherapy studies. [abstract]. ASH Annu. Meet. Abstract 1813.
60. Hamberg, P., Verweij, J. and Sleijfer, S. (2010) (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15, 539-547.
61. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
62. Hanahan, D. and Weinberg, R. A. (2011) The hallmarks of cancer: the next generation. Cell 144, 646-674.
63. Harris, T. J. R. and Mccormick, F. (2010) The molecular pathology of cancer. Nature Rev. Clin. Oncol. 7, 251-265.
64. Hartmann, J. T., Haap, M., Kopp, H. G. and Lipp, H. P. (2009) Tyrosine kinase inhibitorsa review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10, 470-481.
65. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
66. Hershko, A. (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 12, 1191-1197.
67. Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev. Biochem. 67, 425-479.
68. Hiddemann, W. and Dreyling, M. (2003) Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr. Treat. Options Oncol. 4, 219-226.
69. Hideshima, T, Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. and Anderson, K. C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076.
70. Hochstrasser, M. (2009) Origin and function of ubiquitin-like proteins. Nature 458, 422-429.
71. Holden, J. A., Willmore-Payne, C. and Layfield, L. J. (2008) Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp. Mol. Pathol. 85, 68-75.
72. Hu, J., McCall, C. M., Ohta, T. and Xiong, Y. (2004) Targeted ubiquitination of CDT1 by the DDB1 CUL4A-ROC1 ligase in response to DNA damage. Nat. Cell Biol. 6, 1003-1009.
73. Hurwitz, H. I., Dowlati, A., Saini, S., Savage, S., Suttle, A. B., Gibson, D. M., Hodge, J. P., Merkle, E. M. and Pandite, L. (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227.
74. International Myeloma Foundation (2008/2009) Multiple myeloma: concise review of the disease and treatment options [online] http:// www.myeloma.org.
75. Iyer, R. and Bharthuar, A. (2010) A review of erlotinib -an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin. Pharmacother. 11, 311-320.
76. Iyer, R., Fetterly, G., Lugade, A. and Thanavala, Y. (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin. Pharmacother. 11, 1943-1955.
77. Johnson, J. R., Cohen, M., Sridhara, R., Chen, Y. F., Williams, G. M., Duan, J., Gobburu, J., Booth, B., Benson, K., Leighton, J., Hsieh, L. S., Chidambaram, N., Zimmerman, P. and Pazdur, R. (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11, 6414-6421.
78. Kalidas, M., Kantarjian, H. and Talpaz, M. (2001) Chronic myelogenous leukemia. J.A.M.A. 286, 895-898.
79. Kamb, A. (2005) What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161-165.
80. Kamb, A., Wee, S. and Lengauer, C. (2007) Why cancer drug discovery is so difficult? Nature Rev. Drug Discov. 6, 115-120.
81. Kane, R. C., Bross, P. F., Farrell, A. T. and Pazdur, R. (2003) Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513.
82. Kane, R. C., Dagher, R., Farrell, A., Ko, C. W., Sridhara, R., Justice, R. and Pazdur, R. (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 13, 5291-5294.
83. Kane, R. C., Farrell, A. T., Sridhara, R. and Pazdur R. (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12, 2955-2960.
84. Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M.,Bhatia, R, Cervantes, F., Haque, A., Shou, Y., Resta, D. J., Weitzman, A., Hochhaus, A. and le Coutre, P. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546.
85. Keam, S. J. (2008) Dasatinib -In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Biodrugs 22, 59-69.
86. Knight, G. W. and McLellan, D. (2004) Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Br. J. Biomed. Sci. 61, 103-111.
87. Kobayashi, A., Kang, M. I., Okawa, H,. Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K. and Yamamoto, M. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulatefor proteasomal degradation of Nrf2. Mol. Cell Biol. 24, 7130-7139.
88. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715.
89. Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W., Chanan-Khan, A. A. and Orlowski, R. Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281-3290.
90. Kulasingam, V. and Diamandis, E. P. (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5, 588-599.
91. Kummar, S., Chen, H. X., Wright, J., Holbeck, S., Millin, M. D., Tomaszewski, J., Zweibel, J., Collins, J. and Doroshow, J. H. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov. 9, 843-856.
92. Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., Liu, J., Blank, J., Garcia, K.,. Tsu, C., Dick, L., Fleming, P., Yu, L., Manfredi, M., Rolfe, M. and Bolen, J. (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980.
93. Kyle, R. A. and Rajkumar, S. V. (2004) Multiple myeloma. N. Engl. J. Med. 35, 1860-1873.
94. le Coutre, P., Ottmann, O. G., Giles, F., Kim, D. W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., Kuliczkowski, K., Hochhaus, A., Mahon, F. X., Saglio, G., Gobbi, M., Kwong, Y. L, Baccarani, M., Hughes, T., Martinelli, G., Radich, J. P., Zheng, M., Shou, Y. and Kantarjian, H. (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834-1839.
95. Lengyel, E., Sawada, K. and Salgia, R. (2007) Tyrosine kinase mutations in human cancer. Curr. Mol. Med. 7, 77-84.
96. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. and Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23, 1984-1992.
97. Lenz, G., Dreyling, M., Unterhalt, M. and Hiddemann, W. (2004) Current strategies in the treatment of advanced stage mantle cell lymphoma. Dtsch. Med. Wochenschr. 129, 2429-2433.
98. Leonard, J. P., Furman, R. R. and Coleman, M. (2006) Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int. J. Cancer 119, 971-979.
99. Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U. and Dutta, A. (2010) NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70, 10310-10320.
100. Lombardo, L. J., Lee, F.Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S. H., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J. and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
101. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J. and Haber, D. A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
102. Ma, M. H., Yang, H. H., Parker, K., Manyak, S., Friedman, J. M., Altamirano, C., Wu, Z. Q., Borad, M. J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R. A. and Berenson, J. R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136-1144.
103. McDermott, U. and Settleman, J. (2009) Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J. Clin. Oncol. 27, 5650-5659.
104. Manley, P., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M., Cortes, J., Giles, F. and Beran, M. (2005) AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104, 1230-1236.
105. Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., Harapanhalli, R. S,. Dagher, R., Farrell, A., Justice, R. and Pazdur R. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13, 2318-2322.
106. Marblestone, J. G. (2009) Ubiquitin drug discovery & diagnostics 2009 -first annual conference. Idrugs 12, 750-753.
107. Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvator, S., Chella, A., Camplese, P. P., Iarussi, T., Mucilli, F., Mezzetti, A., Cuccurullo, F., Sacco, R. and Buttitta, F. (2005) EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23 857-865.
108. Matthews, D. J. and Gerritsen, M. E. (2010) Tyrosine kinase inhibitors, Targeting protein kinases for cancer therapy. John Wiley & Sons, Inc., New Jersey, USA.
109. McConkey, D. (2010) Proteasome and HDAC: who's zooming who? Blood 116, 308-309.
110. McConkey, D. J. and Zhu, K. (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 11, 164-179.
111. McKeage, K. and Wagstaff, A. J. (2007) Sorafenib: in advanced renal cancer. Drugs 67, 475-483.
112. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L.B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G. and Cherrington, J. M. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337.
113. ® (bortezomib) lable information. [online] http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021602s023lbl.pdf
114. Mitsiades, C. S., Hideshima, T., Chauhan, D., McMillin, D. W., Klippel, S., Laubach, J. P., Munshi, N. C., Anderson, K. C. and Richardson, P. G. (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin. Hematol. 46,166-175.
115. Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Richon, V. M., Marks, P. A. and Anderson, K. C. (2004) Transcriptionalsignature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. U S A. 101, 540-545.
116. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Schlossman, R., Munshi, N. C., Hideshima, T. and Anderson K. C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380.
117. Mok, T. S., Zhou, Q., Leung, L. and Loong, H. H. (2010) Personalized medicine for non-small-cell lung cancer. Expert Rev. Anticancer Ther. 10, 1601-1611.
118. Morabito, F., Gentile, M., Mazzone, C., Bringhen, S., Vigna, E., Lucia, E., Recchia, A. G., Raimondo, F. D., Musto, P. and Palumbo, A. (2010) Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur. J. Haematol. 85, 181-191.
119. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P.W., Biegel, J. A., Hayes, R. L. and Wong, A. J. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55, 5536-5539.
120. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M. and Figlin, R. A. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124.
121. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. and Figlin, R. A. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590.
122. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A. and Miller, P. (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838-4848.
123. Nalepa, G., Rolfe, M. and Harper, J. W. (2006) Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5, 596-613.
124. Nicholson, B. and Kumar, K. G. S. (2011) The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem. Biophys. Published online: 06 April 2011.
125. Nishitani, H., Sugimoto, N., Roukos, V., Nakanishi, Y., Saijo, M., Obuse, C., Tsurimoto, T., Nakayama, K. I., Nakayama, K., Fujita, M., Lygerou, Z. and Nishimoto T. (2006) Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. Embo J. 25, 1126-1136.
126. Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D. S. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16.
127. O'Connor, O. A., Stewart, A. K., Vallone, M., Molineaux, C. J., Kunkel, L. A., Gerecitano, J. F. and Orlowski, R. Z. (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15, 7085-7091.
128. O'Farrell, A. M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W., Wong, L. M., Hong, W., Lee, L. B., Town, A., Smolich, B. D., Manning, W. C., Murray, L. J., Heinrich, M. C. and Cherrington, J. M. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605.
129. O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N. and Druker, B. J. (2005) In vitro activity of Bcr Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505.
130. Orlowski, R. Z. and Kuhn, D. J. (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14, 1649-1657.
131. Oudard, S., Beuselinck, B., Decoene, J. and Albers, P. (2011) Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat. Rev. 37, 178-184.
132. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E. and Meyerson, M. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
133. Pal, S. K. and Figlin, R. A. (2010) Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape. Nat. Rev. Clin. Oncol. 7, 362-363.
134. Pan, Z. Q., Kentsis, A., Dias, D. C., Yamoah, K. and Wu, K. (2004) Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23, 1985-1997.
135. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M. and Varmus, H. (2004) EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U. S. A. 101, 13306-13311.
136. Pei, X. Y., Dai, Y. and Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cellsby the proteasome inhibitor bortezomib and histonedeacetylase inhibitors. Clin. Cancer Res. 10, 3839-3852.
137. Pena, C., Lathia, C., Shan, M. H., Escudier, B. and Bukowski, R. M. (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib Phase III treatment approaches in renal cancer global evaluation trial. Clin. Cancer Res. 16, 4853-4863.
138. Petroski, M. D. and Deshaies, R. J. (2005) Function and regulation of Cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9-20.
139. Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., Pezzoni, G., Allievi, C., Pescalli, N., Cassin, M., di Giovine, S., Nicoli, P., de Feudis, P., Strepponi, I., Roato, I., Ferracini, R., Bussolati, B., Camussi, G., Jones-Bolin, S., Hunter, K., Zhao, H., Neri, A., Palumbo, A., Berkers, C., Ovaa, H., Bernareggi, A. and Inghirami, G. (2008) CEP-18770: a novel, orally active proteasome inhibitor with a tumorselective pharmacologic profile competitive with bortezomib. Blood 111, 2765-2775.
140. Plosker, G. L. and Robinson, D. M. (2008) Nilotinib. Drugs 68, 449-459.
141. Rasheed, W. K., Johnstone, R. W. and Prince, H. M. (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 16, 659-678.
142. Reichert, J. M. and Wenger, J. B. (2008) Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13, 30-37.
143. Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J. L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Blade, J., Boccadoro, M., Cavenagh, J. D., Boral, A. L., Esseltine, D. L., Wen, P. Y., Amato, A. A., Anderson, K. C. and San Miguel, J. (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br. J. Haematol. 144, 895-903.
144. Roberts, P. J., Stinchcombe, T. E., Der, C. J. and Socinski, M. A. (2010) Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28, 4769-4777.
145. Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J. and Gilmer, T. M. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85-94.
146. Sanchez, E., Li, M. J., Steinberg, J. A., Wang, C., Shen, J., Bonavida, B., Li, Z. W., Chen, H. M. and Berenson, J. R. (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br. J. Haematol. 148, 569-581.
147. Sanford, M. and Keating, G. M. (2010) Pazopanib: in advanced renal cell carcinoma. Biodrugs 24, 279-286.
148. Sawyers, C. L. (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4, 343-348.
149. Schenkein, D. (2002) Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 3, 49-55.
150. Schulman, B. A. and Harper, J. W. (2009) Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 10, 319-333.
151. Sequist, L. V., Joshi, V. A., Janne, P. A., Bell, D. W., Fidias, P., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., Verlander, P., Kucherlapati, R., Meyerson, M., Haber, D. A., Johnson, B. E. and Lynch, T. J. (2006) Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin. Cancer Res. 12 (14 Part 2 Suppl S), 4403S-4408S.
152. Shah, J. J., Jakubowiak, A. J., O'Connor, O. A., Orlowski, R. Z., Patterson, M., Harvey, D., Berger, A. J., McDonald, A., Mulligan, G., Petruzzelli, L., Pickard, M. D., Smith, P. G., Venkatakrishnan, K. and Lonial, S. (2009) Phase 1 dose-escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. [abstract]. ASH Annu. Meet. Abstract 1854.
153. Shah, J. J., Harvey, R. D., O'Connor, O. A., Jakubowiak, A. J., Smith, M. R., Orlowski, R. Z., Mulligan, G. J., Smith, P. G., Pickard, M. D., Dezube, B. J. and Lonial, S. (2010) Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a nedd8-activating enzyme inhibitor, in patients with relapsed and/ or refractory multiple myeloma or lymphoma. [abstract]. ASH Annu. Meet. Abstract 2801.
154. Shah, N. P. and Sawyers, C. L. (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389-7395.
155. Shah, N. P., Tran, C., Lee, F.Y., Chen, P., Norris, D. and Sawyers, C. L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401.
156. Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D. S., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
157. Sirotnak, F. M. (2003) Studies with ZD1839 in preclinical models. Semin. Oncol. 30 (1 Suppl 1), 12-20.
158. Sloan, B. and Scheinfeld, N. S. (2008) Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324-1335.
159. Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J. and Pandolfi, P. P. (2008) The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813-817.
160. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B. and Langston, S. P. (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736.
161. Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A. and Brownell, J. E. (2010) The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1, 708-716.
162. Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., Zarba, J. J., Chen, M., McCann, L., Pandite, L., Roychowdhury, D. F. and Hawkins, R. E. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068.
163. Strumberg, D., Voliotis, D., Moeller, J. G., Hilge, R. A., Richly, H., Kredtke, S., Beling, C., Scheulen, M. E. and Seeber, S. (2002) Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40, 580-581.
164. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H. and Khuri, F. R. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058.
165. Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B. and Kondo, S. (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65, 3336-3346.
166. Tang, P., Steck, P. A. and Yung, W. K. (1997) The autocrine loop of TGF-alpha/EGFR and brain tumors. J. Neurooncol. 35, 303-314.
167. Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., Xie, D. L., Zhang, Y. Q. and Klei, H. E. (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790-5797.
168. Uramoto, H. and Mitsudomi, T. (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br. J. Cancer 96, 857-863.
169. US FDA. (2010) Guidance for industry: codevelopment of two or more unmarketed investigational drugs for use incombination. FDA [online], http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM236669.pdf (2010).
170. Vinitsky, A., Michaud, C., Powers, J. C. and Orlowski, M. (1992) Inhibition of the chymotrypsin like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31, 9421-9428.
171. Vivanco, I. and Mellinghoff, I. K. (2010) Epidermal growth factor receptor inhibitors in oncology. Curr. Opin. Oncol. 22, 573-578.
172. Voges, D., Zwickl, P. and Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068.
173. Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J. and Gibson, K. H. (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749-5754.
174. Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright R. D., Gilliland, D. G. and Griffin J. D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
175. Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A. and Griffin, J. D. (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769.
176. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L. E., Bollag, G. and Trail, P. A. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109.
177. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R. and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844.
178. Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J. and Harper, J.W. (1999) The SCF beta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in I kappa B alpha and beta-catenin and stimulates I kappa B alpha ubiquitination in vitro. Genes Dev. 13, 270-283.
179. Wright, J. J. (2010) Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 16, 4094-4104.
180. Wrigley, J. D., Eckersley, K., Hardern, I. M., Millard, L., Walters, M., Peters, S. W., Mott, R., Nowak, T., Ward, R. A., Simpson, P. B. and Hudson, K. (2011) Enzymatic characterisation of USP7 deubiquitinating activity and inhibition. Cell Biochem. Biophys. Published online: 06 April 2011.
181. Wu, S., Chen, J. J., Kudelka, A., Lu, J. and Zhu X. (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9, 117-123.
182. Xia, W., Mullin, R. J., Keith, B. R., Liu, L. H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J. and Spector, N. L. (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255-6263.
183. Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137.
184. Yoshida, M., Shimazu, T. and Matsuyama, A. (2003) Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog. Cell Cycle Res. 5, 269-278.
185. Zavrski, I., Kleeberg, L., Kaiser, M., Fleissner, C., Heider, U., Sterz, J., Jakob, C. and Sezer, O. (2007) Proteasome as an emerging therapeutic target in cancer. Curr. Pharm. Des. 13, 471-485.
186. Zhang, J., Yang, P. L. and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28-39.